Qianyi Wan1, Rui Zhao1, Lin Xia1, Yutao Wu2, Yong Zhou1, Yong Wang1, Yaping Cui1, Xiaoding Shen1, Xiao-Ting Wu3. 1. Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, 37 Guo Xue Rd, Chengdu, 610041, Sichuan Province, China. 2. Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, China. 3. Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, 37 Guo Xue Rd, Chengdu, 610041, Sichuan Province, China. wxt1@medmail.com.cn.
Abstract
PURPOSE: The purpose of this meta-analysis was to assess the associations between inflammatory bowel disease (IBD) and risk of the gastric, small bowel and colorectal cancer. METHODS: We searched the PubMed and Web of Science for observational studies published before June 2020, and the quality of each included study was evaluated according to the Newcastle-Ottawa-Scale. RESULTS: Twenty-six studies comprising 531 449 IBD patients and more than 65 million reference individuals were included. Although IBD was significantly associated with 67% increased risk of the total gastric, small bowel and colorectal cancer. After stratifying by cancer location, IBD mainly increased the risk of intestinal cancer instead of gastric cancer. Furthermore, Crohn's disease (CD) significantly increased the risk of both small bowel cancer and colorectal cancer, while ulcerative colitis (UC) only increased the risk of colorectal cancer. In subgroup analysis, associations between IBD and risk of total gastric, small bowel and colorectal cancer were similar between male and female, except for that male IBD patients but not female had a significantly higher risk of small bowel cancer. Additionally, IBD patients in different geographical areas had different associations with risk of various gastrointestinal tract cancers. CONCLUSIONS: IBD is mainly associated with increased risk of cancers in the lower gastrointestinal tract, including small bowel cancer and colorectal cancer. Because studies about the association between IBD and risk of gastric cancer and the populations in Asia are limited, more observational studies are required in the future.
PURPOSE: The purpose of this meta-analysis was to assess the associations between inflammatory bowel disease (IBD) and risk of the gastric, small bowel and colorectal cancer. METHODS: We searched the PubMed and Web of Science for observational studies published before June 2020, and the quality of each included study was evaluated according to the Newcastle-Ottawa-Scale. RESULTS: Twenty-six studies comprising 531 449 IBDpatients and more than 65 million reference individuals were included. Although IBD was significantly associated with 67% increased risk of the total gastric, small bowel and colorectal cancer. After stratifying by cancer location, IBD mainly increased the risk of intestinal cancer instead of gastric cancer. Furthermore, Crohn's disease (CD) significantly increased the risk of both small bowel cancer and colorectal cancer, while ulcerative colitis (UC) only increased the risk of colorectal cancer. In subgroup analysis, associations between IBD and risk of total gastric, small bowel and colorectal cancer were similar between male and female, except for that male IBDpatients but not female had a significantly higher risk of small bowel cancer. Additionally, IBDpatients in different geographical areas had different associations with risk of various gastrointestinal tract cancers. CONCLUSIONS:IBD is mainly associated with increased risk of cancers in the lower gastrointestinal tract, including small bowel cancer and colorectal cancer. Because studies about the association between IBD and risk of gastric cancer and the populations in Asia are limited, more observational studies are required in the future.
Authors: Oriol de Barrios; Lidia Sanchez-Moral; Marlies Cortés; Chiara Ninfali; Nuria Profitós-Pelejà; M C Martínez-Campanario; Laura Siles; Rosa Del Campo; María Jesús Fernández-Aceñero; Douglas S Darling; Antoni Castells; Joan Maurel; Azucena Salas; Douglas C Dean; Antonio Postigo Journal: Gut Date: 2019-07-31 Impact factor: 23.059
Authors: Jordan E Axelrad; Ola Olén; Michael C Sachs; Rune Erichsen; Lars Pedersen; Jonas Halfvarson; Johan Askling; Anders Ekbom; Henrik Toft Sørensen; Jonas F Ludvigsson Journal: Gut Date: 2020-09-01 Impact factor: 23.059
Authors: Lisa J Herrinton; Liyan Liu; Theodore R Levin; James E Allison; James D Lewis; Fernando Velayos Journal: Gastroenterology Date: 2012-05-15 Impact factor: 22.682
Authors: Sergei Grivennikov; Eliad Karin; Janos Terzic; Daniel Mucida; Guann-Yi Yu; Sivakumar Vallabhapurapu; Jürgen Scheller; Stefan Rose-John; Hilde Cheroutre; Lars Eckmann; Michael Karin Journal: Cancer Cell Date: 2009-02-03 Impact factor: 31.743
Authors: A Losada-García; S A Cortés-Ramírez; M Cruz-Burgos; M Morales-Pacheco; Carlos D Cruz-Hernández; Vanessa Gonzalez-Covarrubias; Carlos Perez-Plascencia; M A Cerbón; M Rodríguez-Dorantes Journal: Front Genet Date: 2022-01-17 Impact factor: 4.599